Nanjing Siling Pharmaceutical Technology

Nanjing Siling Pharmaceutical Technology is a biotechnology company based in China that focuses on the discovery and development of innovative small molecule therapeutics for central nervous system (CNS) disorders. The company utilizes a proprietary drug discovery platform specifically designed to address the challenges of blood-brain barrier penetration and target selectivity. Their current pipeline includes programs targeting neurodegenerative diseases such as Parkinson's disease, as well as psychiatric conditions and chronic pain. Siling Pharma has secured significant venture capital funding from prominent investors like Matrix Partners China and IDG Capital to advance its early-stage candidates. The company is led by a team of experts with deep experience in neuroscience and drug development, aiming to provide transformative treatments for patients with high unmet medical needs.